课题基金 / 基金详情

Preclinical assessment of KAL-ABP target engagement and efficacy using PET, MRI and CSF biomarkers

Preclinical assessment of KAL-ABP target engagement and efficacy using PET, MRI and CSF biomarkers
使用 PET、MRI 和 CSF 生物标志物对 KAL-ABP 靶点参与和功效进行临床前评估
批准号：
364867
负责人：
Kang Min Su
金额：
$0.07万
依托单位：
CIUSSS de l'Ouest-de-l'Ile-de-Montral-Douglas Hospital
依托单位国家：
加拿大
项目类别：
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-01-01 至 2018-01-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=364867&lang=en
关键词：
Ics Travel Awards

项目摘要

项目成果

Kang Min Su的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by multiple pathologies of abnormal aggregates of misfolded proteins: amyloid beta (Ab) and neurofibrillary tangles (NFT). In 2014, the number of people living with
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-scale characterization of molecular and connectomic vulnerability to AD pathology
Amyloid induced hippocampal metabolic network remodelling is associated with memory and cognitive dysfunction
Characterizing the effects of beta-amyloid aggregates on the hippocampal network in Alzheimer's Disease patients and animal models.
Preclinical imaging platform for assessing a novel anti-amyloid therapy